We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Fisher Communications, Inc. (MM) | NASDAQ:FSCI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 41.01 | 0 | 01:00:00 |
Number
of Shares
|
Value
|
||||||
COMMON STOCKS – 59.4%
|
|||||||
CONSUMER DISCRETIONARY – 9.8%
|
|||||||
54,440 |
Lowe's Cos., Inc.
|
$ | 2,292,468 | ||||
53,530 |
Mattel, Inc.
|
2,395,468 | |||||
20,460 |
NIKE, Inc. - Class B
|
1,261,564 | |||||
38,600 |
Omnicom Group, Inc.
|
2,398,218 | |||||
14,900 |
Shimano, Inc.
|
1,147,515 | |||||
41,190 |
Time Warner, Inc.
|
2,404,260 | |||||
36,580 |
Viacom, Inc. - Class B
|
2,410,256 | |||||
14,309,749 | |||||||
CONSUMER STAPLES – 16.7%
|
|||||||
54,404 |
Coca-Cola Co.
|
2,175,616 | |||||
40,940 |
Colgate-Palmolive Co.
|
2,367,970 | |||||
35,510 |
FamilyMart Co., Ltd.
|
1,439,451 | |||||
30,250 |
Heineken N.V.
|
2,104,396 | |||||
14,520 |
Henkel A.G. & Co. KGaA
|
1,181,002 | |||||
14,350 |
L'Oreal S.A.
|
2,418,930 | |||||
22,100 |
Lawson, Inc.
|
1,607,688 | |||||
29,780 |
PepsiCo, Inc.
|
2,405,330 | |||||
28,460 |
Procter & Gamble Co.
|
2,184,590 | |||||
31,250 |
Reckitt Benckiser Group PLC
|
2,234,484 | |||||
52,480 |
Seven & I Holdings Co., Ltd.
|
1,782,591 | |||||
31,520 |
Wal-Mart Stores, Inc.
|
2,358,957 | |||||
24,261,005 | |||||||
HEALTH CARE – 22.2%
|
|||||||
30,620 |
Abbott Laboratories
|
1,122,835 | |||||
41,520 |
Astellas Pharma, Inc.
|
2,120,268 | |||||
31,480 |
Baxter International, Inc.
|
2,213,988 | |||||
19,110 |
Becton, Dickinson and Co.
|
1,884,628 | |||||
61,434 |
Bristol-Myers Squibb Co.
|
2,826,578 | |||||
20,430 |
C.R. Bard, Inc.
|
2,106,129 | |||||
16,880 |
Celgene Corp.
*
|
2,087,212 | |||||
100,700 |
Chugai Pharmaceutical Co., Ltd.
|
2,017,480 | |||||
40,190 |
Eli Lilly & Co.
|
2,136,500 | |||||
29,930 |
Getinge A.B. - B Shares
|
894,468 | |||||
40,160 |
Gilead Sciences, Inc.
*
|
2,187,917 | |||||
24,520 |
Henry Schein, Inc.
*
|
2,361,031 | |||||
19,420 |
Hisamitsu Pharmaceutical Co., Inc.
|
950,005 | |||||
28,530 |
Johnson & Johnson
|
2,401,656 | |||||
78,930 |
Pfizer, Inc.
|
2,149,264 | |||||
21,700 |
Sysmex Corp.
|
1,423,646 | |||||
18,480 |
Zimmer Holdings, Inc.
|
1,450,865 | |||||
32,334,470 |
Number
of Shares
|
|
Value
|
|||||
COMMON STOCKS (Continued)
|
|||||||
INDUSTRIALS – 4.9%
|
|||||||
23,310 |
Cintas Corp.
|
$ | 1,064,218 | ||||
61,130 |
Experian PLC
|
1,124,190 | |||||
21,540 |
Lockheed Martin Corp.
|
2,279,578 | |||||
181,940 |
Southwest Airlines Co.
|
2,578,090 | |||||
7,046,076 | |||||||
INFORMATION TECHNOLOGY – 5.8%
|
|||||||
26,060 |
Adobe Systems, Inc.
*
|
1,118,235 | |||||
66,880 |
CA, Inc.
|
1,826,493 | |||||
2,040 |
Google, Inc. - Class A
*
|
1,775,636 | |||||
26,810 |
SAP A.G.
|
2,006,349 | |||||
46,900 |
Synopsys, Inc.
*
|
1,709,505 | |||||
8,436,218 | |||||||
TOTAL COMMON STOCKS
(Cost $73,098,705)
|
86,387,518 | ||||||
Principal
Amount
|
|||||||
SHORT-TERM INVESTMENTS – 40.4%
|
|||||||
$ | 58,673,685 |
UMB Money Market Fiduciary, 0.01%
1
|
58,673,685 | ||||
TOTAL SHORT-TERM INVESTMENTS
(Cost $58,673,685)
|
58,673,685 | ||||||
TOTAL INVESTMENTS – 99.8%
(Cost $131,772,390)
|
145,061,203 | ||||||
Other Assets in Excess of Liabilities – 0.2%
|
339,812 | ||||||
TOTAL NET ASSETS – 100.0%
|
$ | 145,401,015 |
PLC – Public Limited Company
|
|
*
Non-income producing security.
|
1
The rate is the annualized seven-day yield at period end.
|
|
See accompanying Notes to Schedule of Investments.
|
Cost of investments
|
$ | 131,781,170 | ||
Gross unrealized appreciation
|
$ | 13,566,766 | ||
Gross unrealized depreciation
|
(286,733 | ) | ||
Net unrealized appreciation on investments and foreign currency translations
|
$ | 13,280,033 |
·
|
Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.
|
·
|
Level 2 – Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
|
·
|
Level 3 – Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund’s own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.
|
Level 1
|
Level 2
*
|
Level 3
**
|
Total
|
|||||||||||||
Investments
|
||||||||||||||||
Common Stocks
|
||||||||||||||||
Consumer Discretionary
|
$ | 13,162,234 | $ | 1,147,515 | $ | - | $ | 14,309,749 | ||||||||
Consumer Staples
|
11,492,463 | 12,768,542 | - | 24,261,005 | ||||||||||||
Health Care
|
24,928,603 | 7,405,867 | - | 32,334,470 | ||||||||||||
Industrials
|
5,921,886 | 1,124,190 | - | 7,046,076 | ||||||||||||
Information Technology
|
6,429,869 | 2,006,349 | - | 8,436,218 | ||||||||||||
Short-Term Investments
|
58,673,685 | - | - | 58,673,685 | ||||||||||||
Total Investments
|
$ | 120,608,740 | $ | 24,452,463 | $ | - | $ | 145,061,203 |
*
|
In accordance with procedures established by, and under the general supervision of the Funds’ Board of Trustees, the values of certain equity securities listed or traded on foreign security exchanges may be adjusted due to changes in the value of U.S.-traded securities. In this circumstance, $24,452,463 of investment securities were classified as Level 2 instead of Level 1.
|
**
|
The Fund did not hold any Level 3 securities at period end.
|
(a)
|
The Registrant’s President/Chief Executive Officer and Treasurer/Chief Financial Officer have concluded that the Registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the “1940 Act”)) are effective as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rules 15d-15(b) under the Securities Exchange Act of 1934, as amended.
|
(b)
|
There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) that occurred during the Registrant's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting.
|
Registrant:
|
GaveKal Knowledge Leaders Fund,
a series of the Investment Managers Series Trust |
|
By:
|
/s/ John P. Zader
|
|
Title:
|
John P. Zader, President
|
|
Date:
|
7/30/13
|
By:
|
/s/ John P. Zader
|
|
(Signature and Title)
|
John P. Zader, President
|
|
Date:
|
7/30/13
|
|
By:
|
/s/ Rita Dam
|
|
(Signature and Title)
|
Rita Dam, Treasurer
|
|
Date:
|
7/30/13
|
1 Year Fisher Communications Chart |
1 Month Fisher Communications Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions